Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
Portfolio Pulse from Avi Kapoor
The article highlights three oversold health care stocks with potential for gains in Q4: Organon & Co (OGN), Arcutis Biotherapeutics Inc (ARQT), and TransMedics Group Inc (TMDX). These stocks have RSI values near or below 30, indicating they are oversold. Organon is set to release its Q3 2024 results on Oct. 31, Arcutis received Health Canada approval for ZORYVE Foam, and TransMedics will release its Q3 results on Oct. 28.
October 22, 2024 | 11:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcutis Biotherapeutics has an RSI of 28.13, indicating it is oversold. The stock fell 14% over the past five days. Health Canada approved ZORYVE Foam, which could positively impact the stock.
The RSI suggests ARQT is oversold, and the recent Health Canada approval of ZORYVE Foam could act as a positive catalyst for the stock.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 85
POSITIVE IMPACT
Organon & Co is considered oversold with an RSI of 28.28. The stock has fallen 12% over the past month and is approaching its 52-week low. The company will release its Q3 2024 financial results on Oct. 31, which could impact the stock price.
Organon's RSI indicates it is oversold, suggesting potential for a price rebound. Upcoming Q3 results could provide a catalyst for price movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
TransMedics Group is oversold with an RSI of 29.60. The stock has dropped 22% over the past month. The company will release its Q3 financial results on Oct. 28, which may influence the stock price.
TMDX's RSI indicates it is oversold, suggesting potential for a price increase. The upcoming Q3 results could serve as a catalyst for stock movement.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 75